Campus Universitario Salvatore Venuta

Italy

Campus Universitario Salvatore Venuta

Italy
SEARCH FILTERS
Time filter
Source Type

Celia C.,Methodist Hospital Research Institute | Cosco D.,University of Catanzaro | Paolino D.,University of Catanzaro | Paolino D.,Campus Universitario Salvatore Venuta | And 2 more authors.
Expert Opinion on Drug Delivery | Year: 2011

Introduction: Gemcitabine, an anticancer drug, is a nucleoside analog deoxycytidine antimetabolite, which acts against a wide range of solid tumors. The limitation of gemcitabine is its rapid inactivation by the deoxycytidine deaminase enzyme following its in vivo administration. Areas covered: One of the most promising new approaches for improving the biopharmaceutical properties of gemcitabine is the use of innovative drug delivery devices. This review explains the current status of gemcitabine drug delivery, which has been under development over the past 5 years, with particular emphasis on liposomal delivery. In addition, the use of novel supramolecular vesicular aggregates (SVAs), polymeric nanoparticles and squalenoylation were treated as interesting innovative approaches for the administration of the nucleoside analog. Expert opinion: Different colloidal systems containing gemcitabine have been realized, with the aim of providing important potential advancements through traditional ways of therapy. A possible future commercialization of modified gemcitabine is desirable, as was true in the case of liposomal doxorubicin (Doxil ®, Caely ®). © 2011 Informa UK, Ltd.

Loading Campus Universitario Salvatore Venuta collaborators
Loading Campus Universitario Salvatore Venuta collaborators